Published in Ann Oncol on February 01, 2004
Standardisation of spirometry. Eur Respir J (2005) 48.20
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1994) 25.02
Interpretative strategies for lung function tests. Eur Respir J (2005) 21.50
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
General considerations for lung function testing. Eur Respir J (2005) 7.99
Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J (2005) 7.58
Standardisation of the measurement of lung volumes. Eur Respir J (2005) 7.48
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol (1983) 4.35
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet (1998) 3.83
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet (1999) 3.50
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood (2001) 3.24
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17
Energy balance and colon cancer--beyond physical activity. Cancer Res (1997) 3.11
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol (2007) 2.85
The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther (1971) 2.81
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
Validation of cardiac output studies from the Mostcare compared to a pulmonary artery catheter in septic patients. Minerva Anestesiol (2014) 2.65
The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (1980) 2.64
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol (2008) 2.26
Improved methodology for analyzing local and distant recurrence. J Clin Oncol (1990) 2.21
Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res (2001) 2.17
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol (2003) 2.16
Tamoxifen for breast cancer among hysterectomised women. Lancet (2002) 2.11
A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario. CMAJ (2001) 2.11
Spinal cord injury caused by direct damage by local anaesthetic infiltration needle. Br J Anaesth (2001) 2.06
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol (2007) 2.05
Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol (2001) 2.05
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol (1998) 2.05
Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol (2002) 2.03
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy. Bone Marrow Transplant (2000) 1.95
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol (2000) 1.92
Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol (2000) 1.91
Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med (1991) 1.88
Locoregional recurrence risk after lipofilling in breast cancer patients. Ann Oncol (2011) 1.84
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol (2000) 1.81
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol (2012) 1.79
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol (2000) 1.79
Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet (2001) 1.79
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol (1999) 1.77
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol (2003) 1.75
Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts. Mol Cell (1999) 1.74
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol (2002) 1.73
Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol (2005) 1.72
Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst (1992) 1.70
A computerized diet history questionnaire for epidemiologic studies. J Am Diet Assoc (1994) 1.70
Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol (1996) 1.70
Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol (2007) 1.69
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
Outcome of special types of luminal breast cancer. Ann Oncol (2011) 1.67
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol (2008) 1.66
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol (2000) 1.66
Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med (1994) 1.66
Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol (2010) 1.65
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer (1993) 1.64
Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. Int J Radiat Oncol Biol Phys (1996) 1.63
Sudden death in cancer patient on high-dose domperidone. Lancet (1982) 1.60
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol (2005) 1.60
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst (1996) 1.58
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet (1996) 1.58
Specifications for equipment used for infant pulmonary function testing. ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European Respiratory Society/ American Thoracic Society. Eur Respir J (2000) 1.57
The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol (1990) 1.56
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol (2007) 1.54
Oesophageal cancer treatment: studies, strategies and facts. Ann Oncol (1998) 1.53
Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol (2011) 1.50
Intraductal papillary-mucinous neoplasm of the pancreas. A clinicopathologic entity. Arch Pathol Lab Med (1995) 1.50
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia (2008) 1.49
The trials of Dr. Bernard Fisher: a European perspective on an American episode. Control Clin Trials (1997) 1.49
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol (2001) 1.49
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol (2011) 1.49
Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol (2010) 1.47
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol (1999) 1.47
Meta-analysis: the fashion of summing-up evidence. Part I. Rationale and conduct. Ann Oncol (1991) 1.45
Jaw avascular bone necrosis associated with long-term use of biphosphonates. Ann Oncol (2005) 1.45
Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG) Ann Oncol (1995) 1.45
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia (2012) 1.44